Influencing Factors of Benign Breast Nodules Growth in Women
1.School of Public Health,Tianjin Medical University,Tianjin 300070,China
2.Healthy Management Center,Tianjin Medical University General Hospital,Tianjin 300052,China
*Corresponding author:ZHANG Qing,Chief physician;E-mail:zhangqing@tmu.edu.cn
FAN Na and GAO Ying are the co-first authors
[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. DOI:10.3322/caac.21492.
[2]TORRE L A,SIEGEL R L,WARD E M,et al. Global cancer incidence and mortality rates and trends——an update[J].Cancer Epidemiol Biomarkers Prev,2016,25(1):16-27. DOI:10.1158/1055-9965.EPI-15-0578.
[3]DESANTIS C,MA J,BRYAN L,et al. Breast cancer statistics,2013[J].CA Cancer J Clin,2014,64(1):52-62. DOI:10.3322/caac.21203.
[4]KATALINIC A,EISEMANN N,KRAYWINKEL K,et al. Breast cancer incidence and mortality before and after implementation of the German mammography screening program[J].Int J Cancer,2020,147(3):709-718. DOI:10.1002/ijc.32767.
[5]VAN OURTI T,O'DONNELL O,KO? H,et al. Effect of screening mammography on breast cancer mortality:quasi-experimental evidence from rollout of the Dutch population-based program with 17-year follow-up of a cohort[J].Int J Cancer,2020,146(8):2201-2208. DOI:10.1002/ijc.32584.
[6]ZAHL P H,KALAGER M,SUHRKE P,et al. Quality-of-life effects of screening mammography in Norway[J].Int J Cancer,2020,146(8):2104-2112. DOI:10.1002/ijc.32539.
[7]WARD Z J,SCOTT A M,HRICAK H,et al. Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries:a simulation-based analysis[J].Lancet Oncol,2020,21(8):1077-1088. DOI:10.1016/S1470-2045(20)30317-X.
[8]VON EULER-CHELPIN M,LILLHOLM M,VEJBORG I,et al. Sensitivity of screening mammography by density and texture:a cohort study from a population-based screening program in Denmark[J].Breast Cancer Res,2019,21(1):111. DOI:10.1186/s13058-019-1203-3.
[9]HARVEY J A,BOVBJERG V E. Quantitative assessment of mammographic breast density:relationship with breast cancer risk[J].Radiology,2004,230(1):29-41. DOI:10.1148/radiol.2301020870.
[10]CIATTO S,VISIOLI C,PACI E,et al. Breast density as a determinant of interval cancer at mammographic screening[J].Br J Cancer,2004,90(2):393-396. DOI:10.1038/sj.bjc.6601548.
[11]NOTHACKER M,DUDA V,HAHN M,et al. Early detection of breast cancer:benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review[J].BMC Cancer,2009,9:335. DOI:10.1186/1471-2407-9-335.
[12]SHETTY M K. Screening and diagnosis of breast cancer in low-resource countries:what is state of the art? [J].Semin Ultrasound CT MR,2011,32(4):300-305. DOI:10.1053/j.sult.2011.04.002.
[13]YIP C H,SMITH R A,ANDERSON B O,et al. Guideline implementation for breast healthcare in low- and middle-income countries:early detection resource allocation[J].Cancer,2008,113(8 Suppl):2244-2256. DOI:10.1002/cncr.23842.
[14]ATHANASIOU A,TARDIVON A,OLLIVIER L,et al. How to optimize breast ultrasound[J].Eur J Radiol,2009,69(1):6-13. DOI:10.1016/j.ejrad.2008.07.034.
[15]胡春梅. 超声、MRI及钼靶X线检查在乳腺肿块大小测量中的应用[J].医疗装备,2019,32(3):42-43. DOI:10.3969/j.issn.1002-2376.2019.03.023.
HU C M. Application of ultrasound,MRI and molybdenum target X-ray in the measurement of breast mass size[J].Medical Equipment,2019,32(3):42-43. DOI:10.3969/j.issn.1002-2376.2019.03.023.
[16]DYRSTAD S W,YAN Y,FOWLER A M,et al. Breast cancer risk associated with benign breast disease:systematic review and meta-analysis[J].Breast Cancer Res Treat,2015,149(3):569-575. DOI:10.1007/s10549-014-3254-6.
[17]HARTMANN L C,SELLERS T A,FROST M H,et al. Benign breast disease and the risk of breast cancer[J].N Engl J Med,2005,353(3):229-237. DOI:10.1056/nejmoa044383.
[18]JIANG H,WALTER S D,BROWN P E,et al. Estimation of screening sensitivity and sojourn time from an organized screening program[J].Cancer Epidemiol,2016,44:178-185. DOI:10.1016/j.canep.2016.08.021.
[19]PEER P G,VAN DIJCK J A,HENDRIKS J H,et al. Age-dependent growth rate of primary breast cancer[J].Cancer,1993,71(11):3547-3551. DOI:10.1002/1097-0142(19930601)71:11<3547:aid-cncr2820711114>3.0.co;2-c.
[20]TAGHIPOUR S,BANJEVIC D,MILLER A B,et al. Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study[J].Br J Cancer,2013,108(3):542-548. DOI:10.1038/bjc.2012.596.
[21]WU J C,HAKAMA M,ANTTILA A,et al. Estimation of natural history parameters of breast cancer based on non-randomized organized screening data:subsidiary analysis of effects of inter-screening interval,sensitivity,and attendance rate on reduction of advanced cancer[J].Breast Cancer Res Treat,2010,122(2):553-566. DOI:10.1007/s10549-009-0701-x.
[22]TABAR L,FAGERBERG G,CHEN H H,et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial[J].Cancer,1995,75(10):2507-2517. DOI:10.1002/1097-0142(19950515)75:10<2507:aid-cncr2820751017>3.0.co;2-h.
[23]PACI E,DUFFY S W. Modelling the analysis of breast cancer screening programmes:sensitivity,lead time and predictive value in the Florence District Programme (1975—1986)[J].Int J Epidemiol,1991,20(4):852-858. DOI:10.1093/ije/20.4.852.
[24]TAN K H,SIMONELLA L,WEE H L,et al. Quantifying the natural history of breast cancer[J].Br J Cancer,2013,109(8):2035-2043. DOI:10.1038/bjc.2013.471.
[25]MILLET I,BOUIC-PAGES E,HOA D,et al. Growth of breast cancer recurrences assessed by consecutive MRI[J].BMC Cancer,2011,11:155. DOI:10.1186/1471-2407-11-155.
[26]NAROD S A. Tumour size predicts long-term survival among women with lymph node-positive breast cancer[J].Curr Oncol,2012,19(5):249-253. DOI:10.3747/co.19.1043.
[27]KURIAN A W,MUNOZ D F,RUST P,et al. Online tool to guide decisions for BRCA1/2 mutation carriers[J].J Clin Oncol,2012,30(5):497-506. DOI:10.1200/JCO.2011.38.6060.
[28]BREKELMANS C T,WESTERS P,FABER J A,et al. Age specific sensitivity and sojourn time in a breast cancer screening programme (DOM) in The Netherlands:a comparison of different methods[J].J Epidemiol Community Health,1996,50(1):68-71. DOI:10.1136/jech.50.1.68.
[29]WEEDON-FEKJAER H,LINDQVIST B H,VATTEN L J,et al. Breast cancer tumor growth estimated through mammography screening data[J].Breast Cancer Res,2008,10(3):R41. DOI:10.1186/bcr2092.
[30]TAGHIPOUR S,CAUDRELIER L N,MILLER A B,et al. Using simulation to model and validate invasive breast cancer progression in women in the study and control groups of the Canadian national breast screening studiesⅠ andⅡ[J].Med Decis Making,2017,37(2):212-223. DOI:10.1177/0272989X16660711.
[31]LEE J,KIM D M,LEE A. Prognostic role and clinical association of tumor-infiltrating lymphocyte,programmed death ligand-1 expression with neutrophil-lymphocyte ratio in locally advanced triple-negative breast cancer[J].Cancer Res Treat,2019,51(2):649-663. DOI:10.4143/crt.2018.270.
[32]ORDITURA M,GALIZIA G,DIANA A,et al. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer:a propensity score-matched analysis[J].ESMO Open,2016,1(2):e000038. DOI:10.1136/esmoopen-2016-000038.
[33]SOYANO A E,DHOLARIA B,MARIN-ACEVEDO J A,et al. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies[J].J Immunother Cancer,2018,6(1):129. DOI:10.1186/s40425-018-0447-2.
[34]王立平,蒋天安,杨琛,等. 乳腺良性结节超声BI-RADS分级的可靠性及其影响因素分析[J].中华超声影像学杂志,2011,20(4):314-317. DOI:10.3760/cma.j.issn.1004-4477.2011.04.014.
WANG L P,JIANG T A,YANG C,et al. Reliability investigation and influential factors analysis of BI-RADS-ultrasound categorization on the benign breast nodules[J].Chinese Journal of Ultrasonography,2011,20(4):314-317. DOI:10.3760/cma.j.issn.1004-4477.2011.04.014.